

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
Stephen SCHWERS et al.

Serial No.: 10/524,302 Group Art Unit: Unassigned

Intl. Filing Date: July 28, 2003 Examiner: Unassigned

Title: GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)(3)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the Examiner review and make of record the references identified in this paper. A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

FOREIGN PATENT DOCUMENTS		
Document No.	Publication Date	Country
WO 98/45477	10/15/98	PCT
WO 99/02735	1/21/99	PCT
WO 99/14363	3/25/99	PCT
WO 00/22166	4/20/00	PCT
WO 00/79003	12/28/00	PCT
WO 02/059369	8/1/02	PCT

OTHER DOCUMENTS
BASSO, et al., <i>Interleukin-6 -174 G>C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS)</i> , Arterioscler. Thromb. Vasc. Biol. 22:599-604 (2002).
PEDRO-BOTET, et al., <i>Apolipoprotein E genotype affects plasma lipid response to atrovastin in a gender specific manner</i> , Atherosclerosis 158:183-193 (2001).
PIRMOHAMED, et al., <i>Genetic susceptibility to adverse drug reactions</i> , Trends Pharmacol. Sci. 22:298-305 (2001).
TURNER, et al., <i>Antihypertensive pharmacogenetics: getting the right drug into the right patient</i> , J. Hypertension 19:1-11 (2001).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Office Action on the merits, pursuant to 37 C.F.R. § 1.97(b)(3), no fee is required for filing this Information Disclosure Statement; however, if the Office deems that a fee is necessary to process this paper, the Commissioner is authorized to charge such fee to Deposit Account No. 18-0580.

Respectfully submitted,

By:



David A. Sadewasser
Registration No. 55,587

REED IP LAW GROUP
1400 Page Mill Road
Palo Alto, California 94304
(650) 251-7700 Telephone
(650) 251-7739 Facsimile

F:/Document/1300/0014/Supp IDS.coc

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	1300-0014
-------	---	----	---	------------------------	-----------

Complete if Known

Application Number	10/524,302
Intl. Filing Date	July 28, 2003
First Named Inventor	Stephen SCHWERS, et al.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
	AG	WO 98/45477	10/15/98	PCT			
	AH	WO 99/02735	1/21/99	PCT			
	AI	WO 99/14363	3/25/99	PCT			
	AJ	WO 00/22166	4/20/00	PCT			
	AK	WO 00/79003	12/28/00	PCT			
	AL	WO 02/059369	8/1/02	PCT			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	AM	BASSO, et al., <i>Interleukin-6 -174 G>C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS)</i> , Arterioscler. Thromb. Vasc. Biol. 22:599-604 (2002).	
	AN	PEDRO-BOTET, et al., <i>Apolipoprotein E genotype affects plasma lipid response to atrovastin in a gender specific manner</i> , Atherosclerosis 158:183-193 (2001).	
	AO	PIRMOHAMED, et al., <i>Genetic susceptibility to adverse drug reactions</i> , Trends Pharmacol. Sci. 22:298-305 (2001).	
	AP	TURNER, et al., <i>Antihypertensive pharmacogenetics: getting the right drug into the right patient</i> , J. Hypertension 19:1-11 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.